What is Leerink Partnrs’ Forecast for Ardelyx Q3 Earnings?

Ardelyx, Inc. (NASDAQ:ARDX) – Leerink Partnrs issued their Q3 2025 earnings per share estimates for Ardelyx in a research note issued on Thursday, February 20th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will earn ($0.03) per share for the quarter. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Leerink Partnrs also issued estimates for Ardelyx’s Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.40 EPS and FY2027 earnings at $1.00 EPS.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $116.13 million during the quarter, compared to analyst estimates of $111.16 million. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%.

Other research analysts have also recently issued reports about the company. Piper Sandler upped their price target on Ardelyx from $7.00 to $8.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Raymond James restated a “strong-buy” rating and set a $13.00 price target (down from $15.00) on shares of Ardelyx in a research note on Friday, February 21st. Citigroup decreased their price target on Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. HC Wainwright restated a “neutral” rating and set a $5.50 price target on shares of Ardelyx in a research note on Friday, February 21st. Finally, Cantor Fitzgerald upgraded Ardelyx to a “strong-buy” rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.93.

Ardelyx Trading Up 1.0 %

Shares of Ardelyx stock opened at $5.18 on Monday. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -32.38 and a beta of 0.85. Ardelyx has a fifty-two week low of $4.32 and a fifty-two week high of $9.83. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.58. The stock has a 50 day moving average of $5.29 and a 200 day moving average of $5.63.

Insider Buying and Selling

In related news, CEO Michael Raab sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $5.26, for a total value of $131,500.00. Following the completion of the sale, the chief executive officer now owns 1,150,385 shares in the company, valued at $6,051,025.10. This trade represents a 2.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Laura A. Williams sold 4,941 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $5.62, for a total transaction of $27,768.42. Following the completion of the sale, the insider now owns 303,804 shares of the company’s stock, valued at approximately $1,707,378.48. The trade was a 1.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 141,408 shares of company stock valued at $761,963 over the last quarter. 5.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ardelyx

A number of hedge funds have recently added to or reduced their stakes in ARDX. CWM LLC lifted its position in Ardelyx by 328.1% in the third quarter. CWM LLC now owns 12,814 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 9,821 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Ardelyx by 34.3% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 28,365 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 7,245 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Ardelyx by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 45,280 shares of the biopharmaceutical company’s stock valued at $312,000 after acquiring an additional 17,792 shares during the period. Tyler Stone Wealth Management lifted its position in shares of Ardelyx by 87.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 96,850 shares of the biopharmaceutical company’s stock valued at $667,000 after acquiring an additional 45,055 shares during the period. Finally, Los Angeles Capital Management LLC lifted its position in shares of Ardelyx by 51.8% during the 3rd quarter. Los Angeles Capital Management LLC now owns 170,544 shares of the biopharmaceutical company’s stock valued at $1,175,000 after acquiring an additional 58,219 shares during the period. Institutional investors and hedge funds own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.